drugset
drugset / Trial / NCT05096234

18F-F-AraG PET Imaging to Evaluate Immunological Response to CAR T Cell Therapy in Lymphoma

NCT05096234 ↗

Phase 1 Terminated 2 enrolled Stanford University CellSight Technologies, Inc. · collab
NaSingle-groupOpen-labelDiagnostic

Summary

This is a pilot study in adult subjects with aggressive B-cell lymphoma who will receive commercial or research CAR T cell therapy as anticancer treatment.

Timeline

Start
2021-09-28
Primary completion
2022-05-09
Completion
2023-10-09

Outcome

Outcome not reported

Stopped: “loss of sponsor support”

Drugs

EvaluationDrugModalityDoseRoute
Subject F-ARAG Diagnostic / imaging agent 185 mbq Intravenous

Indications

non-Hodgkin lymphoma